Advertisement

Related Videos

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Ian Tannock, MD, PhD, DSc, on Near-Equivalence: A Better Question Than Non-Inferiority

Leonard B. Saltz, MD, on the Future of Interventional Pharmacoeconomics

Charles Schiffer, MD, on Cost-Effective Use of Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

Advertisement

Advertisement




May
31
Today In Oncology
After the Founder: What a Cervical Cancer Program in Haiti Teaches About Sustaining Prevention
Pain and Health-Related QOL With Darolutamide in Metastatic Hormone-Sensitive Prostate Cancer
Lymph Node Surgery and CDK4/6 Inhibitor Treatment in Early Breast Cancer
ASCO Collaborates With Ryght AI to Accelerate Site Selection for Metastatic Breast Cancer Trial
Behind the Scenes of the 2026 ASCO Annual Meeting
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo